Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Kazi, Dhruv S., Penko, Joanne, Coxson, Pamela G., Moran, Andrew E., Ollendorf, Daniel A., Tice, Jeffrey A., Bibbins-Domingo, Kirsten
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Research Letter
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817484/
https://ncbi.nlm.nih.gov/pubmed/28829863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.9924
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados